While MET amplification confers resistance to anti-EGFR therapies in CRC, this resistance can be overcome by MET kinase inhibitors, which restore sensitivity to EGFR blockade and significantly inhibit tumor growth [41]. The gene discussed is MET; the disease is neoplasm.